Mathieu Ferrari

9PUBLICATIONS
56CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursBiologically active molecules
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jul 01, 2026
CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis.

|Apr 16, 2025
Preclinical development of anti-CD21 chimeric antigen receptor T cells to treat T cell acute lymphoblastic leukemia.

Nicola Maciocia, Malika Hoekx, Ciaran Acuna

|Jan 29, 2025
Reply to: Oligoclonality of TRBC1 and TRBC2 in T cell lymphomas as mechanism of primary resistance to TRBC-directed CAR T cell therapies.

Mathieu Ferrari, Farhaan Parekh, Paul Maciocia

|Nov 11, 2024
TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial.

Kate Cwynarski, Gloria Iacoboni, Eleni Tholouli

|Feb 29, 2024
Dual T-cell constant β chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry.

Pedro Horna, Matthew J Weybright, Mathieu Ferrari

|Feb 21, 2024
Structure-guided engineering of immunotherapies targeting TRBC1 and TRBC2 in T cell malignancies.

Mathieu Ferrari, Matteo Righi, Vania Baldan

Pageof 2

Frequent Collaborators

7 joint publications

Martin Pule

5 joint publications

Paul Maciocia

2 joint publications

Sara Ghorashian

2 joint publications

Persis J Amrolia